In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rebuilding Big Pharma's Business Model

Executive Summary

The blockbuster business model that underpinned Big Pharma's success is now irreparably broken: the costs of commercialization are too high and likely returns below the cost of capital. The industry needs a new approach, constructed from four inter-related building blocks--focused R&D; partnerships; customer solutions, not products; and a business unit, not functional, organizational model.
Advertisement

Related Content

The New Face Of Blockbuster Drugs
The New Face Of Blockbuster Drugs
Collaborating for Better R&D Productivity
Collaborating for Better R&D Productivity
Waking the Giant: Business Model Innovation in the Drug Industry
Imbalanced Innovation: The High Cost of Europe's "Free Ride"
Imbalanced Innovation: The High Cost of Europe's "Free Ride"
R&D Productivity: Not So Bad After All?
Blockbusters to New-Engine Drugs: The Key Industry Shift
Blockbuster Ecosystems: Sustainable Development?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002027

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel